HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits

Ayami Saga, Hanayuki Okura, Mayumi Soeda, Junko Tani, Yuichi Fumimoto, Hiroshi Komoda, Mariko Moriyama, Hiroyuki Moriyama, Shizuya Yamashita, Akihiro Ichinose, Takashi Daimon, Takao Hayakawa, Akifumi Matsuyama

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume412
Issue number1
DOIs
Publication statusPublished - 19-08-2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stem cells
Adipose Tissue
Stem Cells
Cholesterol
Tissue
Rabbits
Pravastatin
Hyperlipoproteinemia Type II
LDL Receptors
Cell- and Tissue-Based Therapy
Serum
LDL Lipoproteins
Lipoproteins
Animals
Regenerative Medicine
Pharmaceutical Preparations
Animal Models

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Saga, Ayami ; Okura, Hanayuki ; Soeda, Mayumi ; Tani, Junko ; Fumimoto, Yuichi ; Komoda, Hiroshi ; Moriyama, Mariko ; Moriyama, Hiroyuki ; Yamashita, Shizuya ; Ichinose, Akihiro ; Daimon, Takashi ; Hayakawa, Takao ; Matsuyama, Akifumi. / HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits. In: Biochemical and Biophysical Research Communications. 2011 ; Vol. 412, No. 1. pp. 50-54.
@article{0e9ee94aaa2b4881832a92d995774b65,
title = "HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits",
abstract = "Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.",
author = "Ayami Saga and Hanayuki Okura and Mayumi Soeda and Junko Tani and Yuichi Fumimoto and Hiroshi Komoda and Mariko Moriyama and Hiroyuki Moriyama and Shizuya Yamashita and Akihiro Ichinose and Takashi Daimon and Takao Hayakawa and Akifumi Matsuyama",
year = "2011",
month = "8",
day = "19",
doi = "10.1016/j.bbrc.2011.07.035",
language = "English",
volume = "412",
pages = "50--54",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits. / Saga, Ayami; Okura, Hanayuki; Soeda, Mayumi; Tani, Junko; Fumimoto, Yuichi; Komoda, Hiroshi; Moriyama, Mariko; Moriyama, Hiroyuki; Yamashita, Shizuya; Ichinose, Akihiro; Daimon, Takashi; Hayakawa, Takao; Matsuyama, Akifumi.

In: Biochemical and Biophysical Research Communications, Vol. 412, No. 1, 19.08.2011, p. 50-54.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits

AU - Saga, Ayami

AU - Okura, Hanayuki

AU - Soeda, Mayumi

AU - Tani, Junko

AU - Fumimoto, Yuichi

AU - Komoda, Hiroshi

AU - Moriyama, Mariko

AU - Moriyama, Hiroyuki

AU - Yamashita, Shizuya

AU - Ichinose, Akihiro

AU - Daimon, Takashi

AU - Hayakawa, Takao

AU - Matsuyama, Akifumi

PY - 2011/8/19

Y1 - 2011/8/19

N2 - Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.

AB - Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.

UR - http://www.scopus.com/inward/record.url?scp=80051798604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051798604&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.07.035

DO - 10.1016/j.bbrc.2011.07.035

M3 - Article

C2 - 21806964

AN - SCOPUS:80051798604

VL - 412

SP - 50

EP - 54

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -